Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin01:26

Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin

653
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
653
ATP Synthase: Mechanism01:48

ATP Synthase: Mechanism

13.9K
In animals, the mitochondrial F1F0 ATP synthase is the key protein that synthesizes ATP molecules through a complex catalytic mechanism. While the nuclear genome encodes the majority of ATP synthase subunits, the mitochondrial genome encodes some of the enzyme's most critical components. The formation of this multi-subunit enzyme is a complex multi-step process regulated at the level of transcription, translation, and assembly. Defects in one or more of these steps can result in decreased...
13.9K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

476
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
476
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

216
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
216
ATP Synthase: Structure01:18

ATP Synthase: Structure

11.9K
ATP synthase or ATPase is among the most conserved proteins found in bacteria, mammals, and plants. This enzyme can catalyze a forward reaction in response to the electrochemical gradient, producing ATP from ADP and inorganic phosphate. ATP synthase can also work in a reverse direction by hydrolyzing ATP and generating an electrochemical gradient. Different forms of ATP synthases have evolved special features to meet the specific demands of the cell. Based on their specific feature, ATP...
11.9K
REM Sleep Behavior Disorder01:15

REM Sleep Behavior Disorder

143
REM Sleep Behavior Disorder (RBD) is a sleep disorder characterized by the absence of muscle paralysis that normally occurs during the REM phase of sleep. This absence allows individuals to physically act out their dreams, which are often vivid and disturbing. Common behaviors exhibited during episodes include kicking, punching, and yelling. These actions can be dangerous, potentially leading to injuries for the person with RBD or their bed partner.
RBD is significantly associated with...
143

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Longitudinal Dynamics of Polyglutamine-Expanded ATXN3 in Biofluids of Spinocerebellar Ataxia Type 3.

Movement disorders : official journal of the Movement Disorder Society·2026
Same author

At Death's Door: Cytosolic Dopamine in Patients With Parkinson Disease.

Neurology·2026
Same author

Segmental and Multifocal Isolated Dystonias: Similarities and Differences.

Movement disorders clinical practice·2025
Same author

Mouse Gnal transcripts and transcriptomics in isolated dystonia.

Research square·2025
Same author

Genetic Diversity and Expanded Phenotypes in Dystonia: Insights From Large-Scale Exome Sequencing.

Annals of clinical and translational neurology·2025
Same author

Genetic Diversity and Expanded Phenotypes in Dystonia: Insights from Large-Scale Exome Sequencing.

medRxiv : the preprint server for health sciences·2024

Related Experiment Video

Updated: Jun 4, 2025

Implantation of Osmotic Pumps and Induction of Stress to Establish a Symptomatic, Pharmacological Mouse Model for DYT/PARK-ATP1A3 Dystonia
10:41

Implantation of Osmotic Pumps and Induction of Stress to Establish a Symptomatic, Pharmacological Mouse Model for DYT/PARK-ATP1A3 Dystonia

Published on: September 12, 2020

7.3K

ATP1A3-Associated Paroxysmal Dystonia.

Mark S Ledoux1,2

  • 1Veracity Neuroscience LLC, Memphis, Tennessee, USA.

Tremor and Other Hyperkinetic Movements (New York, N.Y.)
|December 23, 2024
PubMed
Summary
This summary is machine-generated.

Mutations in ATP1A3 gene cause neurological disorders with varied symptoms. A novel ATP1A3 variant was identified in a patient experiencing paroxysmal dyskinesias, with symptoms improving after treatment with oxcarbazepine and clonazepam.

Keywords:
ATP1A3ataxiadystoniaoxcarbazepineparoxysmal

More Related Videos

Rapid Genotyping of Animals Followed by Establishing Primary Cultures of Brain Neurons
09:51

Rapid Genotyping of Animals Followed by Establishing Primary Cultures of Brain Neurons

Published on: January 29, 2015

16.2K
Measurement & Analysis of the Temporal Discrimination Threshold Applied to Cervical Dystonia
10:05

Measurement & Analysis of the Temporal Discrimination Threshold Applied to Cervical Dystonia

Published on: January 27, 2018

9.7K

Related Experiment Videos

Last Updated: Jun 4, 2025

Implantation of Osmotic Pumps and Induction of Stress to Establish a Symptomatic, Pharmacological Mouse Model for DYT/PARK-ATP1A3 Dystonia
10:41

Implantation of Osmotic Pumps and Induction of Stress to Establish a Symptomatic, Pharmacological Mouse Model for DYT/PARK-ATP1A3 Dystonia

Published on: September 12, 2020

7.3K
Rapid Genotyping of Animals Followed by Establishing Primary Cultures of Brain Neurons
09:51

Rapid Genotyping of Animals Followed by Establishing Primary Cultures of Brain Neurons

Published on: January 29, 2015

16.2K
Measurement & Analysis of the Temporal Discrimination Threshold Applied to Cervical Dystonia
10:05

Measurement & Analysis of the Temporal Discrimination Threshold Applied to Cervical Dystonia

Published on: January 27, 2018

9.7K

Area of Science:

  • Genetics
  • Neurology
  • Molecular Biology

Background:

  • ATP1A3 mutations are linked to diverse neurological syndromes with weak genotype-phenotype correlations and no established treatments.
  • These mutations can present with extra-neural features, complicating diagnosis and management.

Observation:

  • A patient with a novel, highly deleterious ATP1A3 mutation (c.1072G>T;p.Gly358Cys) exhibited recurrent paroxysmal dyskinesias.
  • Clinical features included jaw-opening dystonia, developmental delay, ataxia, and hypotonia, triggered by various stimuli.
  • Paroxysmal episodes were brief (5 min) and responsive to oxcarbazepine and clonazepam.

Findings:

  • The identified ATP1A3 variant (CADD 28.8, REVEL 0.992) is absent in gnomAD v.4.1.0, indicating its rarity and potential pathogenicity.
  • Oxcarbazepine and clonazepam demonstrated efficacy in reducing the frequency of paroxysmal episodes in this patient.

Implications:

  • ATP1A3 mutations should be considered in patients presenting with paroxysmal non-epileptic neurological events, including those overlapping with paroxysmal non-kinesigenic dyskinesias.
  • Multi-gene panel testing for ATP1A3 mutations and variant deleteriousness assessment are crucial for diagnosing non-classical phenotypes.
  • Pharmacological interventions targeting voltage-gated sodium channels, such as oxcarbazepine, may offer therapeutic benefits.